- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05358379
A Study to Investigate THT140, in Subjects With Advanced Solid Tumors and Lymphoma
A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of THT140, an Oral PLK1 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of THT40 administered orally daily. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma with a focus on tumors with ARID1A and similar mutations who have progressed despite having received standard therapy or for whom no standard therapy exists.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Phase 1 part of the study will consist of a dose-escalation and a dose-finding component. Phase 1 also includes expansion cohorts for subject with ARID1A and similar mutations.
Phase 2 will enroll subjects with locally advanced, recurrent, or metastatic, histologically confirmed advanced solid tumors or lymphoma, who have failed all standard therapies or for whom standard therapy does not exist, into 8 groups:
Group 1: Bladder cancer
Group 2: Breast cancer: Triple-negative breast cancer (TNBC)
Group 3: Lung cancer (non-small cell lung cancer [NSCLC] and small cell lung cancer [SCLC])
Group 4: Hepatocellular carcinoma (HCC) and biliary tract cancer (BTC)
Group 5: Metastatic colorectal cancer (mCRC) including KRAS-mutated mCRC
Group 6: B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL)
Group 7: T-cell lymphoma (cutaneous T-cell lymphoma [CTCL] and peripheral T-cell lymphoma [PTCL])
Group 8: Basket cohort: tumor types that are suspected to have a related mechanism of action but are not included in previous groups including, esophageal, prostate, ovarian and pancreatic cancers
Studietype
Registrering (Antatt)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Mark H Kirschbaum, MD
- Telefonnummer: 626-316-3394
- E-post: mark.kirschbaum@tethrabio.com
Studer Kontakt Backup
- Navn: Jason Summa
- E-post: jason.summa@tethrabio.com
Studiesteder
-
-
New York
-
New York, New York, Forente stater, 10065
- Rekruttering
- Memorial Sloan Kettering Cancer Center (MSKCC)
-
Ta kontakt med:
- Horwitz Steven, MD
- Telefonnummer: +1 646-608-2680
- E-post: Horwitzs@mskcc.org
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- MD Anderson Cancer Center
-
Ta kontakt med:
- Rabia Khan
- Telefonnummer: +1 713-563-4667
- E-post: RKhan@mdanderson.org
-
-
Washington
-
Seattle, Washington, Forente stater, 98109
- Rekruttering
- Fred Hutchinson Cancer Center/ University of Washington
-
Ta kontakt med:
- Gentry GT King, MD
- E-post: gking@fredhutch.org
-
-
-
-
-
Barcelona, Spania
- Har ikke rekruttert ennå
- Hospital Universitario Vall d'Hebron
-
Ta kontakt med:
- Maria Vieito, MD
- E-post: Mvieito@vhio.net
-
-
-
-
-
Seoul, Sør -Korea
- Har ikke rekruttert ennå
- Seoul National University Hospital
-
Ta kontakt med:
- Do-Youn Oh, Prof. MD
- Telefonnummer: +82-2-2072-0701
- E-post: ohdoyoun@snu.ac.kr
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
Males or females aged ≥ 18 years.
-
Subjects with histological- or cytological-confirmed, advanced cancer who have progressed on (or not been able to tolerate) standard therapy or for whom no standard anticancer therapy exists
- For Phase 1, all tumor types may be enrolled
- For Phase 2, subjects will be enrolled as per the study design section above
-
ECOG performance status of 0-2.
-
Subjects who relapsed post-autologous or post-allogeneic transplant are eligible. Post-transplant subjects must be without active fungal disease or significant acute graft-versus-host disease
-
Women of childbearing potential (WOCBP) must have a negative pregnancy test (urine or serum) within 7 days prior to starting the study drug. Both males and females must agree to use effective birth control during the study (prior to the first dose and for 6 months after the last dose) if conception is possible during this interval.
-
Subjects must be able to swallow and retain orally administered medication and not have any clinically significant GI abnormalities that may alter the absorption, such as malabsorption syndrome or major resection of the stomach or bowels.
-
Able to agree to and sign the informed consent and to comply with the protocol.
Exclusion Criteria:
-
Subjects with a history of brain metastases or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases. Subjects with treated brain metastases that are asymptomatic and have been clinically stable for at least 4 weeks will be eligible.
-
Subjects who have not received vaccines for severe acute respiratory syndrome-corona virus-2 (SARS-COV-2) and have suspected signs and symptoms of the novel coronavirus infection (COVID-19) or have confirmed COVID-19.
-
Subjects with a history of another primary malignancy, other than:
- In situ carcinomas, e.g., breast, cervix, and prostate
- Locally excised nonmelanoma skin cancer
- No evidence of disease from another primary cancer for 2 or more years and has not taken any anti-cancer treatment in 2 years.
-
Any other clinically significant acute or chronic medical or psychiatric condition or any laboratory abnormality that may increase the risk associated with study drug administration or may interfere with the interpretation of study results.
-
Diseases that significantly affect GI absorption of THT140.
-
Subjects who have impaired cardiac function or clinically significant cardiac disease.
-
Presence of active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment
-
Presence of an active infection requiring intravenous antibiotics
-
Presence of known history of human immunodeficiency virus-1/2 with uncontrolled viral load and on medications that may interfere with metabolism
-
Presence of active hepatitis B virus (HBV) or hepatitis C virus (HCV).
-
Chemotherapy, biologic therapy, targeted therapy, immunotherapy, extended-field radiotherapy, or investigational agents within 5 half-lives or 3 weeks (whichever is shorter) prior to administration of first dose of study drug on Day 1 or have not recovered from the side effects of such therapy.
-
Major surgery/surgical therapy for any cause within 4 weeks of the first dose
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Phase 1 Dose Escalation
Phase 1 = THT140 administered orally in escalating doses starting at 5mg QD M-F week 1 to 3 for 3 weeks of a 4 week cycle. Subsequent cohorts will escalate in dose and schedule until optimized phase 2 dose and schedule is achieved. |
THT140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.
Andre navn:
|
|
Eksperimentell: Phase 2
Phase 2 = Recommended THT140 phase 2 dose and schedule administered orally in 28-day cycles. |
THT140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Maximum tolerated dose
Tidsramme: 6 months
|
The incidence rate of dose-limiting toxicities (first cycle only) at each dose level |
6 months
|
|
Overall Response Rate (ORR)
Tidsramme: 18 months
|
Assessment of response criteria according to RESIST, Lugano or mSWAT. |
18 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Adverse events
Tidsramme: 24 months
|
Type, frequency, and severity of adverse drug reactions |
24 months
|
|
AUC
Tidsramme: 6 months
|
THT140 plasma concentrations |
6 months
|
|
Cmax
Tidsramme: 6 months
|
THT140 plasma concentrations |
6 months
|
|
Tmax
Tidsramme: 6 months
|
THT140 plasma concentrations |
6 months
|
|
T1/2
Tidsramme: 6 months
|
THT140 plasma concentrations |
6 months
|
|
Disease Control Rate
Tidsramme: 24 months
|
To evaluate the disease control rate (DCR) in subjects receiving THT140. |
24 months
|
|
Duration of Response
Tidsramme: 24 months
|
To evaluate the duration of response (DOR) in subjects receiving THT140. |
24 months
|
|
Progression-free Survival
Tidsramme: 24 months
|
To evaluate progression-free survival (PFS) in subjects receiving THT140. |
24 months
|
|
Overall Survival
Tidsramme: 24 months
|
To evaluate overall survival (OS) in subjects receiving THT140. |
24 months
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Pharmacodynamics
Tidsramme: 6 months
|
Pharmacodynamic response to THT140 will be assessed by mRNA sequencing of blood samples to determine differential expression of PLK1 target genes (including MYC, PLK1, CDKN1A) relative to baseline. |
6 months
|
|
Pharmacogenomics
Tidsramme: 24 months
|
Genomic alterations will be assessed by next generation sequencing (NGS) at baseline and various time points during treatment with THT140 in order to investigate the relationship between genetic alterations in THT140 related pathways and response to THT140. Parameters of genetic variations (DNA mutations) and copy number variations using plasma cell-free DNA derived from peripheral blood will be assessed. |
24 months
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- THT140-101
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .